Help understanding blood pathology report

2 Posts | Page(s): 1 

Help understanding blood pathology report

by MedQuestions on Thu Oct 12, 2017 10:37 PM

Quote | Reply

Could someone help me understand what is in this report? A family members was diagnosed with multiple myeloma and I don't understand all of this.

Here are what I think are key phrases:

"The bone marrow shows increased plasma cells accounting for 20-25% of toal nucleated cells baed on CD 138 stain. Plasma cells are monoclonal lambda restricted by immunohistochemical stains for kappa and lambda. The findings are consistent wiht plasma cell neoplasm with the differential diagnosis of plasma cell myelmoa versus smoldering myeloma. 

In the bone marrow section of the report it says:
Plasma cells are increased accounting for 20-25% of total nucleated cells. They are noted in interstitial distribution and in clusters. IHC stains for kappa and lambda shows that plasma cells are lambda restricted.

Assessment on oncology report:

SFLCA abno - ? myeloma - lg A lambda
BMBX - 25% plasma cells
monoclonal gammopathy - free lambda 258 - free kappa 20 - ratio .08
urine bence jones- lambda type

Any information is appreciated.

RE: Help understanding blood pathology report

by Majolica on Fri Oct 13, 2017 02:31 PM

Quote | Reply

Hello,

  Here is some info that can help you.

Plasma Cell Myeloma

Definition
  • Multifocal clonal proliferation of plasma cells based in the bone marrow
    • May be designated as either asymptomatic/smoldering or symptomatic, see below
Alternate/Historical Names
  • Multiple myeloma
  • Myelomatosis
  • Medullary plasmacytoma
  • Kahler’s disease
Diagnostic Criteria
  • Asymptomatic / smoldering vs. symptomatic myeloma are separated based on the presence of complications
    • Asymptomatic / smoldering myeloma requires defined levels of evidence of clonality but lacks complications
      • Elevated M protein (>3g/dL) AND/OR
      • >10% clonal plasma cells in marrow
      • Must not have characteristic clinical complications or end organ/tissue damage
    • Symptomatic myeloma requires any level of evidence of clonality plus characteristic complications
      • Any level of clonal bone marrow plasma cells (usually >10%) OR
      • Any level of M protein in serum or urine
        • Usually >3 g/dL IgG or >2.5 g/dL IgA or
        • >1 g/24 hr urine light chain
      • Must have characteristic clinical complications including:
        • Skeletal destruction with osteolytic lesions, pathological fractures, bone pain
        • Hypercalcemia, anemia, hyperviscosity
        • Renal insufficiency
        • Amyloidosis
    • (MGUScomprises those cases exhibiting both lower levels of M protein and marrow involvement and lacking complications)
  • Variants:
    • Non-secretory myeloma(<5% of cases)
      • Same as above but absence of M protein by immunofixation electrophoresis; detectable by serum free light chain analysis in 2/3 cases
    • Plasma cell leukemia
      • Symptomatic plasma cell myeloma WITH
      • ≥2K/uL or ≥20% circulating clonal plasma cells (frequently lymphocytoid)
      • Frequent extramedullary involvement
  • Morphologic characteristics
    • Distribution: interstitial (clusters not associated with blood vessels), or sheets
    • Plasma cell characteristics:
      • Eccentric nuclei
      • Moderate to abundant basophilic cytoplasm
      • Pale perinuclear “hof” representing the golgi zone.  
    • Variable morphology may be seen:
      • Large cells with prominent nucleoli to small cells with “lymphocytoid” appearance
      • Monotonous to pleomorphic
    • Cytologic atypia:
      • While suggestive, is not diagnostic of plasma cell dyscrasia
      • Nuclear pleomorphism, blastic chromatin most specific
      • Plasmablastic morphology is associated with poorer prognosis
        • Large central nucleolus, dispersed chromatin
        • High N:C ratio, large nucleus
        • Loss of nuclear eccentricity and perinuclear hof

Dita Gratzinger MD PhD ditag@stanford.edu

Department of Pathology
Stanford University School of Medicine
Stanford CA 94305-5342

Initial posting and updates:: 9/1/07, 2/23/08, 4/14/10

Supplemental studies

Immunohistology and Flow
  • Plasma cell quantitation is performed by differential count on the bone marrow aspirate or by immunohistochemistry for CD138 on the bone marrow biopsy
    • Flow cytometry may significantly underestimate plasma cell percentage
      • It does establish clonality and can differentiate residual clonal plasma cells from admixed polytypic plasma cells

Hematolymphoid markers

  • CD45 absent or dim in >99%

B cell and plasma cell markers

  • CD138 >99%
  • CD38 >99%
  • CD79a, most
  • CD20 variable, often absent
  • CD19 variable, often absent
  • CD56 up to 80% -- aberrant antigen
  • Cytoplasmic kappa or lambda light chain by flow cytometry, in situ hybridization, or immunohistochemistry

Other

  • Cyclin D1 (Bcl1) positive plasma cell myelomas often lymphoplasmacytic, CD20+, have better prognosis
Cytogenetics
  • Loss of 13q14
    • Most common abnormality
    • Associated with poor prognosis
  • t(11:14)(q13:q32)
    • Associated with:
      • Cyclin D1 overexpression
      • Lymphoplasmacytic or small lymphocytic morphology
    • Better prognosis
Useful Laboratory Tests
  • Serum or urine protein electrophoresis, immunofixation, light chain quantification
  • Quantitation and typing of monoclonal immunoglobulin / light chain
  • Serum free light chain analysis may be required to demonstrate clonal light chains
  • These studies may be used to
    • Establish presence of a monoclonal plasma cell population
    • Quantitation helps subtype the plasma cell dyscrasia (i.e. >3g/dL serum monoclonal protein is a major criterion for myeloma)
    • Track disease burden over time
Plasma cell leukemia
  • Frequently CD20+, CD56-,  t(11;14)+
  • Frequently unusual M component (non-secretory, IgD, IgE, light chain only)
Differential Diagnosis

  • Reactive plasmacytosis
  • Plasmacytoma
  • Monoclonal gammopathy of uncertain significance
  • Lymphoplasmacytic lymphoma
  • Plasmablastic lymphoma

Plasmacytoma/MyelomaReactive Plasmacytosis
Light chain restriction by flow cytometry, immunohistochemistry or in situ hybridization No light chain restriction

PlasmacytomaMyeloma
Single osseous or extraosseus lesion Lytic bony lesions
No increase away from lesion Usually increased plasma cells on random bone marrow biopsy
No end-organ damage May have end-organ damage

Symptomatic Plasma Cell MyelomaAsymptomatic / Smoldering MyelomaMGUS
Usually but not always >10% clonal plasma cells in bone marrow or plasmacytoma ** ≥10% clonal plasma cells in bone marrow AND/OR <10% clonal plasma cells in bone marrow
M protein in serum or urine or free light chain in urine Serum M-protein >3g/dL Serum M-protein <3g/dL
** Lytic bony lesions or  end-organ damage (hypercalcemia/ anemia/ renal insufficiency etc) No lytic lesions or end-organ damage No lytic lesions or end-organ damage

** Critical points: bone marrow plasma cells or M-protein above threshholds separates asymptomatic myeloma from MGUS and bone or other end organ damage separates symptomatic from asymptomatic myeloma

Plasmacytoma/MyelomaLymphoplasmacytic LymphomaandNodal,ExtranodalandSplenicMarginal Zone Lymphomas
Plasma cells may be pleomorphic or plasmablastic Plasma cell component usually not markedly atypical
Uniform plasma cell morphology Plasma cells mixed with small lymphocytes
IgG or IgA M component most common IgM or IgG M component most common
CD20 often negative CD20 80%
Uniformly CD138 positive Scattered CD138 positive cells
Often CD56+, CD19-, CD45- CD56-, CD19+, CD45+

Plasmablastic LymphomaAnaplastic (Plasmablastic)Plasmacytoma/Myeloma
Plasmablastic morphology Subset plasmablastic
Often HIV+ or otherwise immunosuppressed Usually not immunosuppressed
Often in oral cavity or mucosal areas of head Extraosseous sites overlap
~60% EBV+ usually EBV negative

Plasmacytoma and plasmablastic lymphoma have the same immunophenotype, other than EBV and are generally separated based on clinical grounds

Clinical

  • 15% of all hematologic malignancies
  • Median age 69 years
  • Median survival 3 years
    • May present with / cause bone pain, pathologic fractures, renal failure, hypercalcemia, recurrent infections due to hypogammaglobulinemia
  • Non-secretory variant (1%)
    • No M protein
    • Less renal damage
  • Asymptomatic/smoldering myeloma
    • Minority of patients
    • Initially 10 % annual progression to myeloma
  • Plasma cell leukemia
    • >20% circulating plasma cells
    • Poor survival
Grading / Staging / Report

  • Grading is not applicable
Durie-Salmon Staging System
  • Stage I
    • Hemoglobin >10 g/dL
    • Serum IgG <5 g/dL
    • Serum IgA <3 g/dL
    • Normal serum calcium
    • Urine monoclonal protein excretion <4 g/day
    • No generalized lytic bone lesions
  • Stage II
    • Intermediate between stages I and III
  • Stage III One or more of the following:
    • Hemoglobin <8.5 g/dL
    • Serum IgG >7 g/dL
    • Serum IgA >5 g/dL
    • Serum calcium >12 g/dL
    • Urine monoclonal protein excretion >12 g/day
    • Advanced lytic bone lesions
The pathology report should contain the following information:
  • Diagnosis in the World Health Organization (WHO) classification
    • Equivalent diagnosis in other classifications used by relevant clinicians
  • Results of supplementary studies if performed
  • Relationship to other specimens from the same patient
  • Information relevant to staging if available

 

ListsPlasma cell neoplasms / Immunosecretory disorders (WHO 2008)
  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Plasma cell myeloma
    • Variants:
      • Non-secretory
      • Smoldering
      • Plasma cell leukemia
  • Plasmacytoma
    • Solitary plasmacytoma of bone
    • Extraosseus (extramedullary) plasmacytoma
  • Monoclonal immunoglobulin deposition diseases
    • Primary amyloidosis
    • Systemic light chain and heavy chain deposition diseases
  • Osteosclerotic myeloma(POEMS syndrome)
  • Heavy chain diseases (variants of lymphoma rather than plasma cell neoplasms)
    • Gamma heavy chain disease (seelymphoplasmacytic lymphoma)
    • Mu heavy chain disease (seechronic lymphocytic leukemia)
    • Alpha heavy chain disease /immunoproliferative small intestinal disease(variant of extranodal marginal zone lymphoma)
2 Posts | Page(s): 1 
Subscribe to this message board discussion

Latest Messages

View More

We care about your feedback. Let us know how we can improve your CancerCompass experience.